Additional Information

Description

Calquence (acalabrutinib) 100 mg tablets are a Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of certain hematologic malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) in patients who have received at least one prior therapy. By selectively inhibiting BTK, Calquence disrupts B-cell receptor signaling, reducing the proliferation and survival of malignant B cells.

The mechanism of action involves irreversible binding to BTK, which blocks downstream signaling pathways essential for B-cell activation and survival. This inhibition decreases tumor cell growth and improves disease control. Calquence is administered orally and may be used as monotherapy or in combination with other agents, depending on the specific indication.

Common adverse effects include headache, diarrhea, fatigue, musculoskeletal pain, and upper respiratory tract infections. Serious risks include atrial fibrillation, bleeding, infections, and cytopenias. Patients should be monitored for signs of bleeding, cardiac arrhythmias, and immune suppression.